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Abstract
Background: Paragonimiasis, caused by helminths of the genus Paragonimus spp., is a neglected tropical disease.
Human suffering from paragonimiasis is often misunderstood and its quantification by the disability weight of the
disability-adjusted life years largely varies in different global burden of disease (GBD) estimates. This paper is to
systematically review clinical paragonimiasis cases and requantify the disability weight of human paragonimiasis.
Methods: A systematic analysis was conducted using articles from the following databases: PubMed, Institute for
Scientific Information Web of Science, China National Knowledge Infrastructure, the Chinese scientific journal
databases Wanfang Data and CQVIP, Africa Journal Online, and the System for Information on Grey Literature in
Europe. Search terms were the combination of “paragonim*” with “clinical” or “infection”. Only articles fulfilling the
following conditions were recruited for this study: the occurrence of clinical signs and symptoms of paragonimiasis
in human beings were reported; diagnosis was confirmed; no comorbidities were reported; the reviewed clinical
cases or epidemiological findings were not already included in any other articles. The information and frequencies
of paragonimiasis outcomes from included articles using predefined data fields were extracted two times by two
separate individuals. Outcome disability weights were selected mainly from the GBD 2004 and GBD 2013 datasets.
Frequencies and disability weights of paragonimiasis outcomes were modelled into a decision tree using the
additive approach and multiplicative approach, respectively. Monte Carlo simulations were run 5000 times for an
uncertainty analysis.
Results: The disability weight estimates of paragonimiasis were simulated with 5302 clinical cases from 80 general
articles. The overall disability weight was estimated at 0.1927 (median 0.1956) with a 95% uncertainty interval (UI) of
0.1632–0.2378 using the additive approach, and 0.1791 (median 0.1816) with a 95% UI of 0.1530–0.2182 using the
multiplicative approach. The simulated disability weights of Paragonimus westermani cases were higher than that of
P. skrjabini cases. Lung outcomes and headache were the top two contributors to disability weight for both species.
Conclusions: The use of paragonimiasis disability weight needs to be reconsidered with regard to availability of
morbidity data and species variation. Calculating the disease burden of paragonimiasis requires further modification
and thus has considerable implications for public health prioritization in research, monitoring, and control.
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Background
Paragonimiasis is a neglected tropical disease (NTD) [1]
caused by helminths of the genus Paragonimus spp.,
whose eggs hatch in freshwater and yield motile miracidia.
The miracidia further develop into motile microcercous
cercariae in freshwater snails and later grow into metacer-
cariae in crustaceans like crab or crayfish. Ingestion of
contaminated, undercooked freshwater crabs or crayfish
leads to paragonimiasis [2].
Paragonimiasis is not usually considered a national or re-
gional public health priority, but due to its wide distribution
and severe health consequences in endemic regions, the
disease should not be neglected. Paragonimiasis is endemic
in parts of Africa, North and South America, and particu-
larly in Southeast and East Asian countries such as China,
Japan, and the Philippines [3, 4]. The prevalence of parago-
nimiasis in northeastern India can reach as high as 51.7%
in children aged under 15 years and 18.7% in adults [5].
The disease can also occur in non-endemic areas; for in-
stance, in returning travellers or through infections caused
by internationally traded and contaminated raw freshwater
crab or crayfish [2, 6]. With the gradually increasing aqua-
culture production of freshwater crustacea worldwide [7],
the endemicity and re-emergence of paragonimiasis deserve
more attention [8].
Paragonimiasis causes complex symptoms in multiple
organs. Chest symptoms are its most remarkable clinical
features, as it is mainly in the lung parenchyma that adult
worms exist in pairs encapsulated in fibrous cysts [2, 9].
For some Paragonimus species such as P. skrjabini, only a
few of the parasites develop into adults in the lungs, while
most others migrate to various organs including muscles,
subcutaneous tissue, brain, liver, and so on, at the juvenile
stage [9, 10]. Such ectopic infections can cause a variety of
signs and symptoms including subcutaneous mass, head-
ache, epilepsy, diarrhoea [9, 11, 12].
Probably due to its status as a NTD, suffering from para-
gonimiasis is often misunderstood and its quantification in
the disability weight (DW) of disability-adjusted life years
(DALYs) largely varies in global burden of disease (GBD)
estimates. Fürst et al. [3] estimated the disease burden of
paragonimiasis based on existing DWs pertaining to most
similar outcomes, which were chronic outcomes of lower
respiratory infection for heavy pleuropulmonary infections
Table 1 DWs used in disease burden estimation
Disease burden estimation Outcome Proxy health state Proxy DW Reference
GBD 2016 Asymptomatic paragonimiasis N/A N/A [18]
Heavy paragonimiasis TB, not HIV infected 0.333 (0.224–0.454)
Mild paragonimiasis due to
foodborne trematodiases
COPD and other chronic
respiratory problem, mild
0.019 (0.011–0.033)
Moderate paragonimiasis
due to foodborne trematodiases
COPD and other chronic
respiratory problem, moderate
0.225 (0.153–0.31)
Severe paragonimiasis
due to foodborne trematodiases
COPD and other chronic
respiratory problem, severe
0.408 (0.273–0.556)
Cerebral paragonimiasis Epilepsy, less severe (seizure
< 1 per month)
0.263 (0.173–0.367)
Epilepsy, severe (seizure
≥1 per month)
0.552 (0.375–0.710)
GBD 2013 Asymptomatic paragonimiasis N/A N/A [16, 17]
Heavy paragonimiasis TB, not HIV infected 0.333 (0.224–0.454)
Cerebral paragonimiasis Epilepsy, less severe (seizure
< 1 per month)
0.263 (0.173–0.367)
Epilepsy, severe (seizure
≥1 per month)
0.552 (0.375–0.710)
WHO FERG Paragonimiasis Uncontrolled asthma 0.132 (0.087–0.190) [15, 21, 22]
GBD 2010 Heavy paragonimiasis Abdominopelvic problem: moderate 0.123 (0.083–0.176) [14, 15, 23, 24]
Cerebral paragonimiasis Abdominopelvic problem: moderate 0.123 (0.083–0.176)
Fürst et al. Heavy paragonimiasis Lower respiratory infection 0.099 [3]
Cerebral paragonimiasis Seizure disorders due
to meningitis
0.100
DW Disability weight, COPD Chronic obstructive pulmonary disease, N/A Not applicable, GBD Global burden of disease, WHO FERG World Health Organization
Foodborne Disease Burden Epidemiology Reference Group, TB Tuberculosis, HIV Human immunodeficiency virus
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and seizure disorders due to meningitis for cerebral parago-
nimiasis (see also [13]). The GBD 2010 study used the
newly developed DW of the health status “moderate ab-
dominal pelvic problem” for the outcomes of both heavy
pleuropulmonary and cerebral paragonimiasis [14, 15]. As
it is clinically incorrect, and signs and symptoms of pleuro-
pulmonary and cerebral paragonimiasis do not really match
those of moderate abdominopelvic problems, the GBD
2013 used the DWs for tuberculosis (TB) and epilepsy as
proxies [16, 17]. The GBD 2016 continued with similar
usage, but an extra proxy DWs of chronic obstructive pul-
monary disease (COPD) with different severity levels were
also used [18] (see Table 1). In fact, cases of pleuropulmon-
ary paragonimiasis often present with asthma-, bronchitis-,
and TB-like signs and symptoms, but their general health
state is usually better than that of TB patients [9, 11, 19].
Realizing this and relying on the then most recent DWs
from the GBD 2010 study, the World Health Organization’s
Foodborne Disease Burden Epidemiology Reference Group
(WHO FERG) applied the DW for uncontrolled asthma in-
stead of the more than two times higher DW for TB as a
proxy for pleuropulmonary paragonimiasis in their latest
estimates [15, 20, 21].
The substantial differences in DWs for paragonimiasis
translate into substantial differences in the thus far pub-
lished GBD estimates and thereby limit the usefulness of
all these estimates [3, 20, 22–25]. Also of note is that all
the aforementioned estimates considered only pleuropul-
monary and cerebral paragonimiasis, however, additional
outcomes that were associated with paragonimiasis, such
as pericarditis due to heart involvement, for instance [12],
should also be considered.
Due to all these factors, we systematically reviewed
clinical paragonimiasis cases and applied decision tree
modelling approaches to requantify the DW for human
paragonimiasis.
Methods
Search strategy and selection criteria
The systematic literature search included the databases
PubMed, Institute for Scientific Information (ISI) Web
of Science, China National Knowledge Infrastructure
(CNKI), the Chinese scientific journal databases Wan-
fang Data and CQVIP, Africa Journal Online (AJOL),
and the System for Information on Grey Literature in
Europe (SIGLE). Search terms were the combination of
“paragonim*” with “clinical” or “infection”. Articles were
reviewed by title and abstract, and subsequently full text.
The inclusion criteria were: (i) the articles described the
occurrence of clinical signs and symptoms of paragonimia-
sis in human beings; (ii) the articles reported on paragoni-
miasis only (i.e. articles reporting obvious comorbidities
were excluded); (iii) the diagnosis of paragonimiasis cases
was confirmed by parasitological, serological, or histological
evidence; and (iv) the article reviewed clinical cases or epi-
demiological findings that were not already included in
other articles. The year of the study and the year of publica-
tion were irrelevant in the inclusion/exclusion of articles.
Articles in languages other than English or Chinese, or
without full text available to authors, were excluded. Arti-
cles that selectively reported on a specific case group such
as cerebral paragonimiasis were also excluded. The study
selection process is shown in Fig. 1.
Data extraction and processing
Two authors extracted the information from included arti-
cles. Information was extracted according to the following
predefined data fields: case recruitment method (case re-
views/surveys); region (country, province); Paragonimus spe-
cies; and outcomes reported and their relevant occurrences.
The reported outcomes covered the following items: lung
outcome (chest X-ray/ computed tomography shadow with
symptoms such as fever or cough); pleural outcome (pleural
effusion with symptoms such as chest pain); pericardial out-
come (pericardial effusion with symptoms such as fever or
dyspnea); abdominal pain; hepatomegaly; skin rash; sub-
cutaneous mass; headache; epilepsy; vision impairment;
motor loss; and diarrhea. The frequency of each outcome
was estimated by its relative occurrence in the respective
group.
Another pooling was made with regard to the exact
Paragonimus species. For Chinese articles that did not
report detailed species information, the exact species
was assigned according to the geographic location of the
cases, if applicable. Following this rationale, which is
based on the authors’ experience about the distribution
of paragonimiasis species in China, cases from the Chin-
ese provinces/municipalities Zhejiang, Shanghai, Jiangsu,
Anhui, Jiangxi, Fujian, Jilin, Liaoning, and Beijing were
classified as P. westermani, whereas cases from the prov-
inces Shaanxi, Sichuan, Hubei, Chongqing, Guilin, and
Henan were classified as P. skrjabini. Cases from coun-
tries such as Japan and the US remained in the ‘not fur-
ther specified’ group.
Disability weights for outcomes (see Table 2) were
retrieved in the following order of priority: from the
GBD study, i.e. GBD 2013 [16], GBD 2004 [13], and
finally – if not available from the previous sources – from
other literature.
Decision tree modelling
Decision tree
A decision tree was used to systematically combine the
large set of outcomes and their associated DWs with the
corresponding frequencies to ultimately estimate sum-
mary DWs. The additive approach (Formula 1) was bet-
ter in combining outcomes that presented separately in
individual patients, while the multiplicative approach
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Fig. 1 Article selection flow chart. Figure 1 provides an illustration of the process of how articles were recruited
Table 2 DWs for various outcomes
Outcome DW mean DW uncertainty level Source item Reference
Lung outcomes 0.279 – Lower respiratory infection episodes GBD 2004
Pleural outcomes 0.054 0.035–0.079 Lower back pain, moderate (proxy for chest pain) GBD 2013
Pericardial outcomes 0.252 – Inflammatory heart disease GBD 2004
Headache 0.441 0.294–0.588 Headache, migraine GBD 2013
Epilepsy 0.552 0.375–0.710 Epilepsy, severe GBD 2013
Motor loss 0.061 0.040–0.089 Motor impairment, moderate GBD 2013
Vision impairment 0.031 0.019–0.049 Distance vision impairment, moderate GBD 2013
Diarrhoea 0.074 0.049–0.104 Diarrhea, mild GBD 2013
Abdominal pain 0.060 – Abdominal pain Finkelstein et al. 2007 [26]
Hepatomegaly 0.060 – Mild/moderate hepatomegaly Finkelstein et al. 2007 [26]
Skin rash 0.068 – Oncocerciasis itching GBD 2004
Subcutaneous mass 0.023 – Cutaneous leishmaniasis GBD 2004
DW Disability weight, GBD Global burden of disease
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(Formula 2) was more suitable for combining several out-
comes occurring in one patient [27]. As both conditions
existed, the two approaches were used respectively in the
analysis to compare with each other. Poutcome A represents
the probability/frequency of outcome A; DWoutcome A repre-
sents the DW of outcome A. The total number of outcomes
considered is represented by n in Formulas 1 and 2. All cal-
culations were processed using R software version 3.1.1 (the
R Foundation for Statistical Computing, Vienna, Austria).
DW ¼
Xn
A¼1PoutcomeA  DWoutcomeA ð1Þ
DW ¼ 1−
Xn
A¼1 1−PoutcomeA  DWoutcomeAð Þ ð2Þ
Base case analysis
First, we calculated the base case DW for each group. Sec-
ond, to assess the contribution of each outcome to the
overall DW, we recalculated the DW for each group sup-
posing the specific outcome is missing. If the DW changed
by more than 10%, the outcome was considered critical.
Uncertainty analysis
For each group, an uncertainty analysis was conducted
to explore the range of overall DWs when all formula in-
puts varied simultaneously. In each simulation, each for-
mula input (Poutcome A or DWoutcome A) was selected
randomly from its specific distribution. The distribution
of probability/frequencies followed a beta distribution
estimated using the cases in each group. The distribu-
tion of DWs followed a logit-normal distribution [28] es-
timated from the reported mean and range. In total,
5000 Monte Carlo simulations were performed. After
summarizing all simulations, we demonstrated the un-
certainty interval (UI) by the 2.5 to 97.5% percentile
range of DWs. (For details, see the Additional file 2).
Results
Among the 80 general articles that were included in this
study, 64 did not investigate the species of paragonimiasis.
After estimating using cases’ locations, 38 articles were cat-
egorized in the species group of P. westermani and another
38 in the group of P. skrjabini (see Fig. 1 and Table 3).
Table 3 shows the DWs of the different types of para-
gonimiasis cases. The overall DW estimates of paragoni-
miasis were 0.1927 (using the additive approach) and
0.1791 (using the multiplicative approach), with 5302
clinical cases from 80 general articles. The DWs esti-
mated using the multiplicative approach were generally
lower than those estimated using the additive approach.
The DWs of P. westermani cases were higher than those
of P. skrjabini cases, in both reported and estimated spe-
cies groups. However, DWs simulated with clinical cases
of estimated species showed a smaller gap.
With 5000 Monte Carlo simulations, the findings of
the uncertainty analysis showed the magnitude and ro-
bustness of DW estimates. The median value of DW es-
timates in the uncertainty analysis was 0.1956, with a
95% UI of 0.1632–0.2378 using the additive approach,
while the value was 0.1816 with a 95% UI of 0.1530–
0.2182 using the multiplicative approach (see Table 3).
Table 4 shows the results of a base case analysis of
outcomes. Lung outcomes and headache were the two
outcomes that were critical to the overall DW of parago-
nimiasis, with a greater than 10% change occurring
when the specific outcome was missing from the overall
disability weight estimation.
Table 3 Overall paragonimiasis DW and DWs by species
Type No. of
articles
No. of
cases
Additive approach Multiplicative approach
DW Uncertainty analysis
[median (2.5–97.5%)]
DW Uncertainty analysis
[median (2.5–97.5%]
Overall 80 5302 0.1927 0.1956 (0.1632–0.2378) 0.1791 0.1816 (0.1530–0.2182)
Species reporteda
P. westermani 8 289 0.2829 0.2901 (0.2274–0.3791) 0.2601 0.2660 (0.2121–0.3391)
P. skrjabini 7 701 0.0827 0.0860 (0.0676–0.1115) 0.0804 0.0836 (0.0659–0.1078)
Other 2 130 0.2073 0.2212 (0.1646–0.2983) 0.1951 0.2067 (0.1563–0.2729)
Unknown 64 4182 0.2044 0.2077 (0.1745–0.2493) 0.1889 0.1917 (0.1629–0.2272)
Species estimationa
P. westermani 38 1132 0.2464 0.2507 (0.2067–0.3102) 0.2255 0.2291 (0.1913–0.2801)
P. skrjabini 38 3459 0.1739 0.1770 (0.1496–0.2097) 0.1622 0.1650 (0.1408–0.1934)
Other 2 581 0.2073 0.2212 (0.1646–0.2983) 0.1951 0.2067 (0.1563–0.2729)
Unknown 3 130 0.1971 0.2014 (0.1537–0.2694) 0.1877 0.1912 (0.1468–0.2543)
aOne article reported clinical symptoms of both P. westermani and P. skrjabini cases
DW Disability weight
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The differences in DW estimates between various
types of paragonimiasis were further analysed by com-
paring outcome contributions to the overall estimates.
Figure 2 shows the comparison of the outcome prob-
ability, DW contribution, and its percentage share (using
the additive approach) between P. westermani cases and
P. skrjabini cases. Lung outcomes and headache were the
top two contributors to DW estimates for both species.
Compared to P. skrjabini cases, lung outcomes were more
probable to occur in P. westermani cases and had more
percentage share, thus bringing more contributions to the
overall DW estimate of the latter species. Subcutaneous
Table 4 Base case analysis of outcomes
Outcome No. of cases
with the
outcome
Occurrence rate
of cases with
the outcome (%)
Overall DW % change without the outcome
Additive approach Multiplicative approach
Lung outcomes 1425 26.88 38.91 37.16
Pleural outcomes 1341 25.29 7.09 6.35
Pericardial outcomes 271 5.11 6.68 5.98
Headache 614 11.58 26.50 24.67
Epilepsy 90 1.70 4.86 4.34
Motor loss 86 1.62 0.51 0.45
Vision impairment 23 0.43 0.07 0.06
Diarrhoea 268 5.05 1.94 1.72
Abdominal pain 879 16.58 5.16 4.60
Hepatomegaly 685 12.92 4.02 3.58
Skin rash 168 3.17 1.12 0.99
Subcutaneous mass 1391 26.24 3.13 2.78
DW Disability weight
Fig. 2 Outcome comparison by species. Figure 2 shows the comparison of the outcome probability, DW contribution, and its percentage share
between Paragonimus westermani cases and P. skrjabini cases. DW: Disability weight
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mass was more likely to occur in P. skrjabini cases, but re-
sulted in less impact to its DW estimates compared with
P. westermani cases (see Fig. 2).
Discussion
Our study simulated the overall DW estimate of paragoni-
miasis at 0.1927 (median 0.1956) using the additive ap-
proach and 0.1791 (median 0.1816) using the multiplicative
approach. The estimated DW of P. westermani was higher
than that of P. skrjabini. Lung outcomes and headache con-
tributed the greatest to DW estimates.
Compared with the GBD 2010 study, this study found
considerably higher DWs than the health status of
“moderate abdominal pelvic problem” (0.123) that Salo-
mon et al. [15, 28] used as a proxy for the outcomes of
both heavy paragonimiasis and cerebral paragonimiasis.
However, abdominal pelvic problem is never the domin-
ant manifestation even if sometimes abdominal organs
could be involved [2].
Our DW estimates are also higher than those Fürst et
al. [3] used for heavy paragonimiasis (0.099) and cerebral
paragonimiasis (0.100). The reason could be that we in-
cluded more outcomes in our model, such as headache
and pericardial symptoms. The necessity of these extra
outcomes was manifested by their non-negligible contri-
bution to the overall DW. However, our DW estimates
were lower than either the heavy paragonimiasis or cere-
bral paragonimiasis DWs used in GBD 2013 and GBD
2016 [16–18], as they focus on more severe situation
with higher worm burden or cerebral involvement. The
application of the two different types of DWs in the
years lived with disability (YLD) calculation shall have to
match with different incidence/prevalence rates. How-
ever, it was often difficult to find the morbidity informa-
tion relating to heavy/cerebral paragonimiasis for a
specific region in the literature search [18]. Therefore,
the overall paragonimiasis DW estimated in this study
that match just overall incidence/prevalence rate in YLD
calculation could better fit the data paucity situation.
Our result is higher than the health status DW per-
taining to acute episode of severe infectious disease
(0.133) and a bit lower than that of post-acute effects
(fatigue, emotional lability, and insomnia) of infectious
diseases (0.219) as outlined in GBD 2013 [16, 24]. Com-
pared with Clonorchis sinensis, another foodborne
trematode disease, our estimate is higher than the DW
simulated by Qian et al. [29] using data collected from a
field survey. Compared with the DW Finkelstein et al.
[26] estimated for schistosomiasis using a decision tree
(0.132), our result is also higher. Apart from the differ-
ence between diseases, the reason could be partly due to
data sources. Most of our recruited articles were case
reviews based on clinical cases that referred to hospitals
as field surveys were either unavailable or reported
insufficient information. This may be associated with the
overestimation of the severity of a disease.
We further found that headache contributed more to
the DW estimation than epilepsy. Headache is probably
a neglected outcome for cerebral paragonimiasis in dis-
ease burden estimation. None of the GBD studies [3, 15,
18, 30] considered headache as an important outcome of
cerebral paragonimiasis. In a FERG estimation to com-
pare DALYs of foodborne diseases, the DW of paragoni-
miasis also just considered the epilepsy outcome of
cerebral symptoms [21]. Although paragonimiasis DALY
ranked high in a comparison of foodborne diseases [22],
it could still be underestimated with the neglect of head-
ache impact to the DW used in calculation.
Our study generated DWs estimated using the additive
approach and the multiplicative approach. The result
showed that the DW estimated using the additive
approach was generally higher than that estimated using
the multiplicative approach. The limitation of the addi-
tive approach could be one of the reasons. Using this
approach, the combined DW could exceed 1.0 and over-
estimation could occur when different outcomes affect
the same health domain [27] (e.g. the lung outcome and
the pericardial outcome could both lead to symptoms in
the chest).
The DWs of P. westermani were higher than that of
P. skrjabini for both reported and estimated species. For
the reported species, their simulated 95% UIs did not
overlap, while for the estimated species, their simulated
95% UIs overlapped for both the additive approach and
the multiplicative approach. As the overlapped part was
relatively small and the species was estimated based on
the authors’ experiences, we still consider the difference
to be somewhat significant. It was inferred that a pos-
sible reason could be the biological difference between
the two species. P. westermani larvae develop into adult
worms in the human lung, while only a few P. skrjabini
larvae develop into adults in the same location. Most of
the latter remain in the juvenile stage, migrating to dif-
ferent organs and causing damage [10]. Therefore, the
analysis of outcome percentage share of the estimated
DWs further showed that compared with P. westermani,
the estimated P. skrjabini cases had higher percentage of
extra-pulmonary outcomes.
In our study, only two articles with the species P. africa-
nus and P. miyazaki were included in the modelling. The
simulated DW was in between those of P. westermani and
P. skrjabini. It was further inferred that some other species
might be similar to P. westermani in DW estimates as they
mainly cause pulmonary symptoms, including P. africa-
nus, P. heterotremus, P. uterobilateralis, P. kellicotti, and
P. mexicanus. These species distribute across West Africa,
South and Southeast Asia, and North and South America
[2]. Some other species could be similar to P. skrjabini
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with ectopic forms more common, such as P. miyazaki
from Japan, which is very close morphologically and mo-
lecularly to P. skrjabini from China [2].
We recognize that our study had some limitations. We
excluded case reviews in languages other than Chinese
and English due to article availability and language bar-
riers. We missed articles with full text non-available to
us. This may bring bias to our study, however, we tried
to minimize impact as most of the missed 32 articles
were published earlier than in 1995. We also omitted
some scarce outcomes such as spinal symptoms and eye
symptoms, which may lead to an underestimation of the
overall DW. In the uncertainty analysis, we replaced the
missing range of some outcome DWs with the average
value of available uncertainty levels. This may result in
our uncertainty results having lower credibility. In
addition, as most Chinese cases did not report species
information, we estimated the species based on authors’
experiences on species information collected from cases
in the same location. This kind of estimation may reduce
the solidity of species classification.
Despite these potential limitations, our estimation of the
DW of paragonimiasis helps to close the gap in the
current disease burden system, particularly for NTDs. In
low- and middle-income countries, such as China, parago-
nimiasis is increasingly becoming a potential threat, as the
production and consumption of crayfish, the second inter-
mediate host, has greatly risen in recent years. The
national production of crayfish increased by 36.59% in
2017 compared with 2016, and for some provinces, the
rate was as high as 141.05%; meanwhile, the number of
crayfish-specific restaurants boomed in major cities like
Shanghai and Guangzhou [31]. We call for more attention
on this chronic disabling and death threatening “poverty
disease” [32]. More studies are needed in areas related to
paragonimiasis assessment, prevention, and treatment.
Conclusions
Our study systematically estimated the DWs of parago-
nimiasis from reported cases for the first time. P. wester-
mani was found to have higher DW estimates than P.
skrjabini. These could bring considerable changes to dis-
ease burden estimation, thus having an impact on health
policymaking and resource allocation in research, moni-
toring, and control, particularly when faced with the po-
tentially increasing threat of paragonimiasis in low- and
middle-income countries.
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